Drug treatments known as GLP-1 agonists have rapidly altered eating patterns across the United States in 2026, prompting food makers and restaurant chains to change menus, portioning and product formulas. A KFF Health Tracking Poll conducted Oct. 27–Nov. 2 found roughly one in eight U.S. adults is currently taking a GLP-1 medication, and companies from packaged-food giants to fast-food chains are responding to lower calorie intake and fewer restaurant visits. Analysts warn the shift could erase tens of billions in industry sales by 2030 even as some firms see an opening to capture new shoppers with higher-protein, higher-fiber and smaller-portion offerings. The unfolding change is driven both by rising adoption and by new oral versions of GLP-1 drugs that are making treatment more accessible.
Key takeaways
- About 1 in 8 U.S. adults report current GLP-1 use, with 18% saying they have taken one at some point (KFF, Oct. 27–Nov. 2 survey).
- Adults on GLP-1 drugs consume about 21% fewer calories and cut grocery spending by nearly one-third on average, according to KPMG data cited in industry research.
- J.P. Morgan estimates annual U.S. food-and-beverage sales could fall by $30 billion to $55 billion by 2030 if adoption keeps rising; it projects more than 30 million Americans could be on GLP-1 treatments by 2030 (about 10 million in 2026).
- Surveys from EY-Parthenon and UBS show large behavioral shifts: ~70% of those eating fewer calories say they snack less, and ~60% report dining out less often.
- Dinner visits among regular GLP-1 users have fallen about 6%, and Bernstein analysts say visit frequency can drop as much as 45% depending on category and occasion.
- Major companies are responding with product changes: protein-forward snacks, fiber-rich reformulations and smaller portion sizes have been rolled out or tested across the sector.
- Novo Nordisk launched a Wegovy oral pill in January 2026, and Eli Lilly plans an oral GLP-1 rollout; analysts expect pills to increase overall adoption.
Background
GLP-1 agonists were developed to treat Type 2 diabetes but gained attention for weight loss after trials showed significant sustained reductions in appetite and body weight. The drugs slow gastric emptying, increase satiety and blunt hunger signals, producing changes in how often and what many people eat. Initially delivered by injection, the class is now expanding into oral formulations, lowering the barrier for people who avoid injections and likely broadening the user base.
Food manufacturers and restaurant chains rose on decades of demand for larger portions, snack occasions and impulse purchases. That model depends on frequent snacking, caloric consumption and beverage purchases — revenue lines that interact directly with the appetite-reducing effects of GLP-1 medicines. Investors and analysts began flagging the potential revenue exposure in 2025–2026 as adoption accelerated and as several large food companies started publicly discussing strategy shifts.
Main event
On Dec. 8, 2025 a photo circulated showing Clinton Hall’s “Teeny Weeny Mini Meal” next to a regular combo in New York City — a visual shorthand for how portioning and menu design are adapting. Across the sector, firms are testing smaller servings, higher-protein recipes and fiber-forward snacks to appeal to people whose appetite and calorie budgets have tightened. Chains such as Chipotle and Olive Garden have introduced grab-and-go protein cups and lighter-portion menus, respectively, while snack and beverage incumbents are promoting product variants that emphasize protein, fiber or hydration.
Executives have given mixed public signals. Domino’s CEO Russell Weiner said the pizza chain has not yet seen material sales declines, suggesting shareable dinner occasions may be more resilient. PepsiCo’s CEO Ramon Laguarta described both risks and opportunities as the company launched protein Doritos and fiber-rich SunChips varieties. McDonald’s leadership pointed to existing protein choices and said the company is experimenting with beverage and portion options to match changing preferences.
Smaller players and category specialists are also pivoting. Nestlé launched a frozen brand positioned for GLP-1 users and later labeled products as “GLP-1 friendly,” which executives say boosted sales. J&J Snack Foods, whose grocery business is 13.5% of sales, is adding protein to soft pretzels and releasing a smaller Luigi’s mini pop with antioxidants and hydration-focused tweaks for freezer-aisle buyers and experiential venues like stadiums.
Analysis & implications
Category effects will be uneven. High-frequency, low-calorie-density categories that rely on snacking and sugary beverages face steeper near-term pressure: surveys indicate roughly 70% of calorie-reducing GLP-1 users snack less, and many report cutting sugary drinks and alcohol. By contrast, shareable meals, premium dining experiences and protein-forward items may prove more resilient or even grow if marketed effectively to users focused on muscle preservation and satiety.
Economically, a reduction in per-capita caloric intake has outsized revenue implications because many snack and beverage purchases are low-margin, high-frequency transactions. J.P. Morgan’s $30 billion–$55 billion range to 2030 hinges on sustained, growing adoption; if oral pills accelerate uptake above current forecasts, downside could skew toward the higher end. However, the shift also catalyzes product innovation that can recapture some spend through premium pricing or reformulated offerings.
Behavioral dynamics add complexity. Data show about 5% of users lapse from GLP-1 therapy for reasons including cost, side effects or achieving weight goals; many maintain lower-calorie habits temporarily after stopping. That on/off pattern may produce cyclical demand rather than a single permanent reduction, complicating forecasting for manufacturers and restaurateurs. The advent of oral GLP-1s is broadly expected to raise adoption, but persistence rates on pills versus injectables remain uncertain.
Comparison & data
| Metric | Reported change | Source |
|---|---|---|
| Calorie intake | ≈21% fewer calories | KPMG (industry analysis) |
| Grocery spending | ~30% lower spending among users | KPMG |
| Dinner traffic | ↓ 6% among regular users | RRD (Dana Baggett) |
| Restaurant visit frequency | Up to ↓ 45% by category/occasion | Bernstein research note |
These figures show the categories most affected and underline why companies are prioritizing protein, fiber and portion control during product development. Differences by income, occasion (breakfast vs. dinner) and product type mean some segments will contract more than others, creating pockets of both risk and opportunity.
Reactions & quotes
Industry strategists and executives have framed the changes as both manageable challenges and chances to innovate. Experts emphasize adjusting product composition, labeling and serving size to align with evolving consumer physiology and preferences.
“Whether it is labeling as GLP-1 friendly, decreasing the serving size, emphasizing protein content … there are a number of players that are starting to react to this.”
Don K. Johnson, EY-Parthenon
Johnson’s remark underscores consulting firms’ guidance to clients: innovate around nutrient density and portioning to keep GLP-1 users engaged. Firms that repackage existing strengths (protein, fiber, hydration) can preserve revenue while attracting health-focused buyers.
“I think there are more opportunities than threats, but there are both.”
Ramon Laguarta, PepsiCo CEO
Laguarta’s comment, made on an earnings call, explains why PepsiCo is expanding protein and fiber lines. Executives at other firms similarly argue that proactive portfolio shifts can blunt downside and open new revenue streams.
“Dinner, for us, is a sharing occasion, so perhaps that’s why we’re not seeing any impact, but we’re going to continue to watch it.”
Russell Weiner, Domino’s Pizza CEO
Weiner’s view highlights variability by occasion: shareable meals and social dining may be less vulnerable than solo snacking and quick bites.
Unconfirmed
- Whether oral GLP-1 pills will deliver higher long-term adherence than injectables remains unclear; available data are preliminary.
- Exact persistence and quit rates for pill versus injectable users have not been firmly established and may vary by demographic and cost factors.
- The scale and timing of industry revenue loss depend heavily on adoption curves and on how quickly companies reformulate or reposition products.
- Reported changes to alcohol consumption among GLP-1 users are survey-based and may not translate uniformly across regions or income groups.
Bottom line
Widespread GLP-1 use is already reshaping eating and drinking behavior for a growing share of Americans, producing measurable declines in snacking, some restaurant visits and low-nutrient purchases. That trend represents a material economic risk for segments of the food-and-beverage industry but also a commercial opening for firms that move quickly to offer protein- and fiber-rich, smaller-portion and hydration-focused items.
Executives and investors should prepare for a multi-year transition marked by uneven category impacts, cyclical user behavior and faster adoption if oral pills broaden the market. Companies that combine product innovation with clear labeling and targeted marketing may recoup lost occasions and build new loyal customers among health-conscious consumers.